Charles River/$CRL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Charles River
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
- Ticker
- $CRL
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 19,000
- Headquarters
- Wilmington, United States
- Website
- www.criver.com
Charles River Metrics
BasicAdvanced
$15B
-
-$4.88
1.41
-
Price and volume
Market cap
$15B
Beta
1.41
52-week high
$312.26
52-week low
$146.20
Average daily volume
934K
Financial strength
Current ratio
1.348
Quick ratio
0.796
Long term debt to equity
1.048
Total debt to equity
1.048
Interest coverage (TTM)
5.29%
Profitability
EBITDA (TTM)
849.118
Gross margin (TTM)
34.59%
Net profit margin (TTM)
-5.96%
Operating margin (TTM)
14.06%
Effective tax rate (TTM)
-28.65%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
4.11%
Return on equity (TTM)
-7.52%
Valuation
Price to revenue (TTM)
3.796
Price to book
5.22
Price to tangible book (TTM)
-30.25
Price to free cash flow (TTM)
40.963
Free cash flow yield (TTM)
2.44%
Free cash flow per share (TTM)
7.587
Growth
Revenue change (TTM)
-0.74%
Earnings per share change (TTM)
255.12%
3-year revenue growth (CAGR)
-1.45%
10-year revenue growth (CAGR)
10.36%
3-year earnings per share growth (CAGR)
-19.73%
10-year earnings per share growth (CAGR)
5.13%
What the Analysts think about Charles River
Analyst ratings (Buy, Hold, Sell) for Charles River stock.
Analyst projections of the future price of Charles River stock.
Bulls say / Bears say
Drug Safety Assessment demand is showing a credible recovery. Q2 net bookings rose 12.6% sequentially to $701m, the book-to-bill ratio reached 1.19x and backlog grew to $1.97bn; Charles River also raised its 2026 organic revenue and earnings guidance. (Charles River Laboratories)
The portfolio clean-up could lift profitability. Selling the lower-priority CDMO, Cell Solutions and European discovery assets sharpens the focus on core testing, while greater control of non-human-primate supply is expected to improve costs and support further margin expansion. (Charles River Laboratories, StockAnalysis)
Charles River is building growth options in higher-value services. Its 2030 plan targets 5%–7% annual organic growth and roughly 24% operating margins, with bioanalysis, in-vitro testing, AI-assisted discovery and the Apollo platform intended to benefit from more complex biologics research. (BioSpace, Morningstar)
The Research Models and Services business remains weak. Charles River expects a low- to mid-single-digit organic decline for 2026, as lower North American small-model volumes and constrained academic and government spending outweigh better demand from Chinese clients. (Charles River Laboratories, The Motley Fool)
The reported recovery still carries significant costs. Q2 revenue fell 2.7% year on year, Charles River made a GAAP loss after divestiture charges, and higher study costs and corporate expenses reduced the non-GAAP operating margin from a year earlier. (Charles River Laboratories, Insider Monkey)
The demand rebound is not yet proven to be durable. Management said early-stage biotech funding had not yet recovered in its CRADL business, pricing remained weaker than desired and it wanted several more strong booking quarters before calling the improvement a trend. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 24 Sept 2026.
Charles River Financial Performance
Revenues and expenses
Charles River Earnings Performance
Company profitability
Upcoming events
No upcoming events
Charles River News
AllArticlesVideos
Funds containing Charles River
AllUSDEURGBP
Fund name | Fund size | $CRL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.43% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.43% |
iShares Healthcare Innovation£DRDR | £1B | 1.43% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.27% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.27% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.